Key Highlights

  • Adjusted EPS of USD 0.59 topped the USD 0.56 estimate and rose from USD 0.54.
  • Revenue of USD 411.2 million missed the USD 414.25 million estimate despite 2.5% organic growth.
  • Flood damage at the Cincinnati facility cut third-quarter revenue by about USD 7 million.
  • A USD 2.1 billion refinancing closed on Oct. 19 and includes 9.5% senior secured notes.

Integra LifeSciences (NASDAQ:IART) reported third-quarter results on Wednesday, Oct. 21, with adjusted EPS of USD 0.59, above the USD 0.56 estimate. Revenue of USD 411.2 million fell short of the USD 414.25 million estimate, though it was up 2.3% reported and 2.5% organic from a year earlier. GAAP EPS was USD 0.19, versus a loss of USD 0.07 in the prior-year quarter.

Integra is a medical technology company focused on neurosurgery and tissue reconstruction. Shares were down 12.6% at USD 11.65 in Wednesday trading.

Flood Disruption in Cincinnati

The company said flooding at its Cincinnati manufacturing facility reduced third-quarter revenue by roughly USD 7 million. Management said the effect was larger than first anticipated, and it estimates a further USD 15 million to USD 20 million revenue impact in the fourth quarter. Most of the remaining headwind sits in the MAYFIELD neurosurgery product family.

Chairman and Chief Executive Officer Stuart Essig said the company continues to plan for a return to full manufacturing in the second quarter of next year. Revenue excluding the flood impact would have been near the midpoint of the prior guidance range, according to the company's financial chief.

Segment Results Diverged

Specialty Surgery, about 70% of revenue, posted sales of USD 304.1 million, up 4.2% organically. Neurosurgery grew 6.5% organically despite the flood, led by CereLink, Certas Plus, Bactiseal and DuraSeal. Instruments declined 0.9% on order timing and ENT fell 1.1%.

Tissue Reconstruction revenue was USD 107.1 million, down 2.2%. DuraSorb and PriMatrix grew, but declines in MicroMatrix and Integra Skin outweighed them. Management cited competitive pressure, a slower pace of share recovery and sales force turnover in its UBM line, which includes MicroMatrix, and said it now sees Tissue Reconstruction flat for the full year.

Adjusted gross margin was 61.1%, compared with 62.9% a year earlier, reflecting lost gross profit from Cincinnati and product mix. Adjusted EBITDA was USD 79.8 million, or 19.4% of revenue, against USD 78.5 million, or 19.5%.

Guidance and Refinancing

The release restated guidance first issued on Oct. 2. Full-year revenue is guided to a range from USD 1.634 billion to USD 1.654 billion, and adjusted EPS to a range from USD 2.30 to USD 2.40. Fourth-quarter revenue is guided to a range from USD 413 million to USD 433 million, a reported change of negative 5.2% to negative 0.5%, with adjusted EPS from USD 0.61 to USD 0.71.

Operating cash flow was USD 96.0 million, which the company described as a record for a quarter. Net debt was USD 1.5 billion and the leverage ratio improved to 3.8 times.

On Oct. 19, the company completed a USD 2.1 billion refinancing, made up of a USD 1.65 billion senior secured credit facility and USD 450 million of 9.5% senior secured notes due in 2033. Management said it adds about USD 8 million of interest expense in the fourth quarter and another USD 24 million in the following year versus its updated outlook. The amended covenants temporarily raise the maximum net leverage ratio, with step-downs to 4.25 times during next year.

Items to Watch

The markers include fourth-quarter revenue against the guided range, the pace of the Cincinnati recovery and the second-quarter restart target, and the limited commercial launch of SurgiMend planned for December. Leverage against the target range of 2.5 to 3.5 times, interest expense after the refinancing and Tissue Reconstruction trends are also on the list.